2月5日，工业和信息化部等八部门印发《中药工业高质量发展实施方案（2026—2030年）》（以下简称 《实施方案》）。 《实施方案》提出了未来五年的发展目标：到2030年，中药工业全产业链协同发展体系初步形成，重点 中药原料持续稳定供应能力进一步增强，数智化、绿色化水平明显提升，一批关键技术取得突破，产业 协同创新水平显著提高。 设置四大目标 根据工业和信息化部消费品工业司披露的解读，《实施方案》着力推进产业政策、监管政策、医保政策 和临床使用政策的有效协同；充分发挥地方政府发展中药工业的积极性，鼓励各地因地制宜先行先试； 将原料的持续稳定供应作为产业链供应链稳定的"牛鼻子"；将支持中药工业龙头企业发展壮大、不断提 高行业集中度作为重中之重。 《实施方案》重点围绕发展质量、协同体系、创新产品、数智化绿色化转型升级等方面设置了具体的任 务目标。 一是发展质量明显提高，中药工业规模效益稳步提升，产业集约化程度明显提高，质量管理水平显著提 升，培育一批引领带动能力突出的中药工业领航企业，培育60个高标准中药原料生产基地。 二是协同体系更加健全，中药材种植加工、中药研发生产、流通服务等上下游各环节协同更加紧密，建 设 ...

Group 1 - The total cash dividends distributed by nearly 20 companies in the Shanghai market before the Spring Festival will amount to 25.8 billion yuan, with the total dividends expected to exceed 347.6 billion yuan by the end of 2025 [1] - As of February 5, 2025, 321.8 billion yuan has already been distributed, with Industrial Bank set to distribute over 11.9 billion yuan on February 6, 2025, at a rate of 0.565 yuan per share (tax included) [1] - The banking sector is the main contributor to cash distributions before the Spring Festival, with nine banks announcing a total of nearly 70 billion yuan in dividends for the first half of 2025 [1] Group 2 - The change in the dividend rhythm and frequency among bank stocks reflects the implementation of the "pre-Spring Festival dividend" policy, enhancing investor experience by providing clearer cash returns [2] - Traditional companies, including Yangtze Power and Darentang, are also distributing cash dividends before the Spring Festival, with Yangtze Power set to distribute over 5.1 billion yuan on February 12, 2025 [2] - Darentang announced a cash dividend of 2.45 yuan per share, totaling 1.887 billion yuan, with a cumulative cash dividend of 5.117 billion yuan since its listing in 2001 [2] Group 3 - Jianfa Co. announced a cash dividend of 2.00 yuan per 10 shares, totaling approximately 579.9 million yuan, which accounts for 50.49% of its net profit for the first three quarters of 2025 [3] - The continuous strengthening of cash dividend regulations and disclosure requirements by regulatory authorities is enhancing shareholder return awareness among listed companies [3] - Investors are increasingly focusing on companies that can withstand economic cycles while consistently returning value to shareholders, marking a significant path for value investment [3]

此外，主要内容还包括整理特色炮制技术、方剂配伍和用药规范，建立完善质量控制体系；开发优 势民族药新产品，培育民族药名品；全方位推动中成药产品临床价值和市场价值双提升；加强中药工业 国际交流合作，鼓励开展优势中成药产品国际注册等。 新华社北京2月5日电（记者周圆）记者5日获悉，工业和信息化部等八部门日前联合印发《中药工 业高质量发展实施方案（2026—2030年）》，提出到2030年，中药工业全产业链协同发展体系初步形 成，重点中药原料持续稳定供应能力进一步增强，数智化、绿色化水平明显提升，一批关键技术取得突 破，产业协同创新水平显著提高。 主要目标还包括，到2030年，培育一批引领带动能力突出的中药工业领航企业，培育60个高标准中 药原料生产基地；建设5个中药工业守正创新中心；推动一批中药创新药获批上市，新培育10个中成药 大品种，推动一批医疗机构中药制剂转化为中药创新药；制修订10项中药工业数智技术相关行业标准， 发布20个数智化转型升级典型案例，建设20个智能工厂、培育10个绿色工厂。 方案以稳定供应、协同创新、智能制造、产品推广、服务体系构建为抓手，统筹推进六个方面共15 项任务，包括加快制修订中药材生 ...

Core Insights - The Ministry of Industry and Information Technology and eight other departments have issued the "Implementation Plan for the High-Quality Development of Traditional Chinese Medicine Industry (2026-2030)", aiming to establish a collaborative development system for the entire industry chain by 2030 [1] - The plan emphasizes enhancing the stable supply capacity of key traditional Chinese medicine raw materials, improving digital and green transformation levels, and achieving breakthroughs in key technologies [1] - The initiative aims to cultivate 60 high-standard traditional Chinese medicine raw material production bases and establish five innovation centers for the traditional Chinese medicine industry [1] Market-Related Areas - The policy encourages the use of modern scientific technology and traditional Chinese medicine research methods to study the efficacy and mechanisms of traditional Chinese medicine, which will lead to increased R&D investment and accelerated product iteration [1] - The continuous implementation of national and provincial standards for traditional Chinese medicine granules and slices will unify industry standards, posing short-term cost control challenges for some companies but ultimately benefiting larger enterprises with comprehensive industry chain advantages [2] - The current policy environment supports the inheritance and innovation of traditional Chinese medicine culture, providing a favorable market for the value return of branded traditional Chinese medicine [2]

全文如下： 中药工业高质量发展实施方案（2026-2030年） 2月5日，工信部等八部门印发《中药工业高质量发展实施方案（2026—2030年）》，方案提 出，到2030年，中药工业全产业链协同发展体系初步形成，重点中药原料持续稳定供应能力进 一步增强，数智化、绿色化水平明显提升，一批关键技术取得突破，产业协同创新水平显著提 高。发展质量明显提高，中药工业规模效益稳步提升，产业集约化程度明显提高，质量管理水 平显著提升，培育一批引领带动能力突出的中药工业领航企业，培育60个高标准中药原料生产 基地。协同体系更加健全，中药材种植加工、中药研发生产、流通服务等上下游各环节协同更 加紧密，建设5个中药工业守正创新中心。创新产品持续涌现，推动一批中药创新药获批上 市，新培育10个中成药大品种，推动一批医疗机构中药制剂转化为中药创新药。数智化、绿色 化转型升级取得突破，制修订10项中药工业数智技术相关行业标准，推动建设一批数智化创新 载体和公共服务平台，支持企业开展数智化改造提升，发布20个数智化转型升级典型案例，建 设20个智能工厂、培育10个绿色工厂。 中医药是中华文明的瑰宝，中药工业是中医药现代化发展的重要支撑， ...

盘后，中药产业迎来政策利好！ 2月5日下午消息，工信部等八部门印发《中药工业高质量发展实施方案（2026—2030年）》（以下简称"实施 方案"）。其中提到，到2030年，培育一批引领带动能力突出的中药工业领航企业，培育60个高标准中药原料 生产基地。推动一批中药创新药获批上市，新培育10个中成药大品种，推动一批医疗机构中药制剂转化为中药 创新药。 实施方案提到，引导中药工业龙头企业聚焦重点原料品种，充分发挥资金、技术、渠道等优势，在主产区因地 制宜建设一批高标准中药原料生产基地；加强中药领域科技成果转化和推广应用，培育壮大中药工业新质生产 力；运用人工智能、大数据等新一代信息技术，构建经典名方、名老中医经验方等特色方剂知识图谱和图神经 网络；提升中药饮片集约化生产水平，加快制定实施全国中药饮片炮制规范、配方颗粒国家标准，持续完善饮 片质量标准体系；支持临床机构开展中药新药临床试验，构建中药新药研发开放式协作体系，加速新药发现和 创新，缩短研发周期，降低研发成本。 工信部等八部门重磅发布 工信部等八部门印发《中药工业高质量发展实施方案（2026—2030年）》，目标到2030年，中药工业全产业链 协同发展体系 ...

Core Viewpoint - The Ministry of Industry and Information Technology, along with eight other departments, has issued the "Implementation Plan for the High-Quality Development of Traditional Chinese Medicine Industry (2026-2030)", aiming to establish a collaborative development system for the entire traditional Chinese medicine (TCM) industry chain by 2030 [1] Group 1: Development Goals - By 2030, the TCM industry aims to enhance the stable supply capacity of key TCM raw materials and significantly improve digitalization and greening levels [1] - A number of key technologies are expected to achieve breakthroughs, leading to a notable increase in collaborative innovation levels within the industry [1] - The quality of development in the TCM industry is projected to improve significantly, with steady growth in scale and efficiency, and a marked increase in industrial intensification [1] Group 2: Industry Structure and Innovation - The plan includes the cultivation of 60 high-standard TCM raw material production bases and the establishment of five TCM industrial innovation centers [1] - There is an emphasis on the continuous emergence of innovative products, with the goal of approving a number of TCM innovative drugs for market release and nurturing ten major varieties of traditional Chinese medicine [1] - The transformation and upgrading towards digitalization and greening are expected to achieve breakthroughs, including the revision of ten industry standards related to TCM digital technology [1] Group 3: Infrastructure and Support - The initiative will support enterprises in digital transformation and enhancement, with the publication of 20 typical cases of digital transformation and the construction of 20 smart factories and 10 green factories [1]

盘龙药业公告称，2023年9月公司向特定对象发行935.27万股，发行价32.29元/股，募集资金总额3.02亿 元，净额2.95亿元。公司此前与保荐机构及相关银行签订《募集资金三方监管协议》。截至公告披露 日，用于"中药配方颗粒研发及产业化项目"的中国银行西安软件园支行账户（账号103307746042）已无 余额，于2026年办理注销手续，对应监管协议同步终止。 ...

Core Viewpoint - The A-share market experienced a decline in early trading, but major financial sectors such as banks and brokerages provided support, leading to a mixed performance across various sectors, with significant activity in consumer and emerging concepts [1] Market Performance - The three major A-share indices closed lower, with the Shanghai Composite Index down 26.29 points (0.64%) at 4075.92, the Shenzhen Component down 203.56 points (1.44%) at 13952.71, and the ChiNext Index down 51.24 points (1.55%) at 3260.28 [1] - Total market turnover reached 2.19 trillion yuan, with over 3700 stocks declining [1] Sector Highlights - Major financial sectors, including banks and brokerages, showed strong performance, with Xiamen Bank hitting a ceiling price, marking a new high since June 2021, and Chongqing Bank rising over 7% [1] - Consumer sectors, including media, tourism, food and beverage, retail, and healthcare, saw collective gains, with stocks like Haixin Food and Anji Food hitting ceiling prices [1] - New consumption concepts such as the "grain economy" and "pet economy" also experienced upward momentum, reflecting positive market expectations for consumer recovery [1] - AI application concepts rebounded, with stocks in AI animation, marketing, and media rising, including companies like Qunxing Toys and Yaowang Technology hitting ceiling prices [1] - Real estate concepts continued to strengthen, with multiple stocks like Jingtou Development and Huangting International hitting ceiling prices, adding vibrancy to the market [1] Declines in Specific Sectors - The non-ferrous metals, gold, and silver sectors faced significant declines, with stocks like Silver Nonferrous and Hunan Silver hitting their lower limits [2] - The photovoltaic industry chain, including space photovoltaic and equipment, saw a sell-off, with stocks like Junda Co. and Shuangliang Energy hitting their lower limits [2] - The power equipment sector also declined, with companies like Zhongheng Electric and Keshida hitting their lower limits [2] - The semiconductor and storage chip sectors continued to retreat, with stocks like Juguang Technology and Changfei Optical Fiber experiencing significant declines [2] Insights from Analysts - Dongfang Securities noted that the recent rebound after a significant drop indicates a stronger expectation for market stability, suggesting a potential shift towards a "slow bull" market [7] - Tianfeng Securities highlighted that this year's "Spring Festival excitement" may be more sustained due to policy expectations and trends in household investment towards equity assets, with consumer demand expected to release earlier than in previous years [8] - CITIC Securities identified low-orbit communication satellite chains as a key investment hotspot in the commercial aerospace industry, anticipating a transition from technology validation to large-scale industrialization around 2026 [8]

Core Viewpoint - The Chinese medicine ETF (560080) has shown positive performance with most constituent stocks rising, indicating a favorable market sentiment towards the Chinese medicine sector [1][6]. Group 1: Stock Performance - Major stocks in the Chinese medicine ETF have seen significant gains, with Da Ren Tang rising over 4%, Pian Zai Huang over 3%, and Tong Ren Tang over 2% [1]. - The estimated weights and performance of key stocks include: - Yunnan Baiyao at 10.56% with a 1.47% increase - Pian Zai Huang at 9.21% with a 3.78% increase - Dong E E Jiao at 6.18% with a 0.73% increase [2]. Group 2: Technological Advancements - The launch of the first "Traditional Chinese Medicine Brain-Machine Interface" equipment marks a significant technological advancement, aimed at treating neurological disorders [3]. - This technology integrates brain-machine interface with acupuncture, showcasing innovation in the field of traditional medicine [3]. Group 3: Policy Developments - The implementation of the "Drug Administration Law Implementation Regulations" emphasizes a review system for traditional Chinese medicine based on traditional theories, human experience, and clinical data [4]. - The regulations aim to ensure the safety and traceability of traditional Chinese medicine products, which may lead to industry consolidation and growth for leading companies [4]. Group 4: Investment Opportunities - Three main investment themes in the Chinese medicine sector are identified: 1. Price governance, focusing on competitive products and companies that can leverage price reductions for volume growth [5]. 2. Consumption recovery, driven by macroeconomic improvement and an aging population, benefiting companies with strong brand and product advantages [7]. 3. State-owned enterprise reform, which may enhance performance through efficiency improvements in state-controlled companies [8]. Group 5: Market Activity - The Chinese medicine ETF (560080) has seen increased trading activity, with a transaction volume nearing 1 billion yuan and significant capital inflow over recent days [6].